Novo prepares for phase 3 trial with promising weight-loss candidate

Novo Nordisk continues to develop new treatments alongside its successful weight loss drugs. The company is advancing amycretin to phase 3 of development for treating overweight and obesity, following promising earlier studies showing a significant weight loss after 36 weeks. Research Director Martin Lange expressed satisfaction with regulatory feedback allowing this progression. Phase 3 trials are expected to start next year’s first quarter. January results of amycretin phase 1b/2a studies showed an average 22% weight loss, increasing Novo’s stock by 7.1%. Concurrently, Novo is developing Cagrisema, combining semaglutide with cagrilintide, displaying a 22.7% weight loss in phase 3 data, contrary to the 25% expected by investors, which lowered stock prices. Novo announced new 80-week phase 3 trials for Cagrisema, involving approximately 600 participants.